Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Clinical Benefits
Mechanism of Action
Cagrilintide is a long-acting amylin receptor agonist that activates amylin receptors in the brain and gastrointestinal tract. Amylin is naturally co-secreted with insulin from pancreatic beta cells and plays a crucial role in appetite regulation and glucose homeostasis. By activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, cagrilintide provides potent appetite suppression. It also slows gastric emptying, reduces glucagon secretion, and enhances insulin sensitivity, complementing GLP-1 pathway activation.
Proven Results
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.